Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

THC Biomed Intl Ltd C.THC

Alternate Symbol(s):  THCBF

THC Biomed Intl Ltd. is a Canada-based cannabis producer. The Company’s principal business is the production and sale of cannabis through THC BioMed Ltd., which is a small batch Licensed Producer as regulated by the Cannabis Act which regulates the production, distribution, and possession of cannabis for both medical and adult recreational access in Canada. The Company’s biological assets consist of cannabis plants (mother plants and clones for growth); resin; oil; harvested marijuana flowers prior to completion of the drying, grading and testing processes; and edible concentrate. The Company operates in a single reportable segment being the cultivation and sale of cannabis. Its subsidiaries include THC BioMed Ltd., Clone Shipper Ltd., THC BioMed Victoria Falls Ltd., THC2GO Dispensaries Ltd. (THC2GO), and THC BioMed Lesotho Ltd. (THC Lesotho). Clone Shipper Ltd. owns all rights to the Clone Shipper product used to transport live plants.


CSE:THC - Post by User

Post by Greencashon Aug 16, 2020 9:19am
171 Views
Post# 31414215

Cannabis Canada: Cheaper pot might be the way to go for Cana

Cannabis Canada: Cheaper pot might be the way to go for Cana

It took some time, but Canadian cannabis producers appear to have finally embraced selling cheaper pot. 

The so-called value segment of the Canadian cannabis market - defined by one analyst as having a retail price below $6 per gram - has exploded in recent months: it accounted for slightly more than 40 per cent of all dried flower sales in July, up from 10 per cent of the market last September, according to industry data provider Headset. 

The popularity of these “value" products has helped companies like Aurora Cannabis Inc. and Canopy Growth Corp. report better-than-expected quarterly sales figures, while also providing consumers with a competitively priced product that could lure people away from the illicit market. 

"The value segment is really aimed at getting people in [the legal market], but the producer's job is to keep that customer and then trade them up to more expensive products," said Graeme Kreindler, an analyst with Eight Capital, in a phone interview. 

But their prevalence may come at a price. By selling more cheap pot, cannabis companies may risk hurting their margins as well as sacrificing additional revenue despite being able to clear out inventory much faster, some analysts say. 


RELATED 


There were more than 669,000 kilograms of unpackaged dried flower stored in cannabis producers' vaults across Canada in May, according to recent Health Canada figures. That could take well over a year to clear out assuming no more pot is produced in the country and if inventory isn't destroyed.

"What's been interesting to me was how some of the Canadian producers didn't understand that they could maintain higher prices per volume on flower products," said Stifel Financial Corp. analyst Andrew Carter in an interview. 

"With excess capacity, there's always going to be someone that eventually decides to undercut everyone else."

That's what happened in October when Hexo Corp. launched its Original Stash brand, which sold about one ounce of cannabis for approximately $125, a price point that would match similar products found on the illicit market. Now, there is roughly a dozen cannabis producers who are selling similar sized options to the recreational market.

Carter said Canopy Growth recently embraced the value segment with cheaper bulk options after the company lost market share and needed to spur sales. 

"If they can focus on growth, then maybe [Canopy] can win back some of its market share," he said.

 
 
 
Bloomberg Markets To win in cannabis, you need to win the recreational market: Canopy Growth CEO 
 
 
To win in cannabis, you need to win the recreational market: Canopy Growth CEO 

Canopy Growth CEO David Klein says his company intends to have top market share in each recreational segment which means improving flower quality and encouraging the entry of non-smoking consumers into the cannabis space through topicals and beverages.

Earlier this week, David Klein, chief executive officer at Canopy Growth, said that the value segment of the market is likely to command about half of the overall recreational market. 

However, it might take a few more years for the Canadian cannabis market to show the various distinctive segments of the market such as value offerings or premium brands, he added.  

"The consumer is just defaulting to the highest THC for the lowest price right now," Klein told BNN Bloomberg in a phone interview. 

"Most of the [consumer-packaged-goods] categories like to define themselves by price points, but I don't know if the price points have been established yet in a meaningful way. We'll only know that once we go through this transition from the illicit market to the legal market."

While B.C.-based Tilray Inc. does offer a value product under its The Batch brand, it hasn't been a strategic focus for the company, said RBC Capital Markets analyst Douglas Miehm, in a recent research note. 

"[Tilray] is targeting sales from higher-margin products, which in our view could hinder its revenue and [earnings before interest, taxes, depreciation, and amortization] ramp," he wrote. 

Tilray CEO Brendan Kennedy said in an interview that he doesn't see cheaper cannabis on the legal market stopping customers from buying the pot producer's more expensive premium offerings. Indeed, he said people who are more interested in higher-quality products with better terpene profiles or visual appeal aren't the target market for value brands.

"A net new value consumer is coming from the illicit market, generally, and not coming from a premium segment of the market. So I don't see cannibalization," Kennedy said. "If we see the value market growing over time, that's probably a good thing because those value consumers are migrating from the illicit market."


<< Previous
Bullboard Posts
Next >>